MEMPHASYS
REPRODUCTIVE BIOTECHNOLOGY

ASX Release **18 September 2026**
ASX Code: MEM

Memphasys Secures ~A$674,000 Felix™ Agreement as European Expansion Accelerates

Czech Republic, Slovakia and Kazakhstan added to growing European footprint

Highlights

- ~A$674,000 (€416,200) minimum contracted purchases under a new three-year exclusive Felix™ commercial agreement covering the Czech Republic, Slovakia and Kazakhstan
- Contracted minimum purchases increase from ~A$139,000 in Year 1 to ~A$310,000 in Year 3, providing a defined pathway to growing recurring revenue as Felix™ adoption builds.
- **Large addressable market of ~89,600 ART cycles across the contracted territories**, including ~54,300 in the Czech Republic, 8,288 in Slovakia and 27,012 in Kazakhstan, which also supports 7,000 publicly funded IVF/ICSI treatment quotas annually.
- New European commercial lead now employed, providing dedicated in-market support to INVIDO and Memphasys' growing distributor network to accelerate Felix™ commercialisation and adoption across Europe.

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") has further expanded the European commercial footprint of its Felix™ System, signing a three-year exclusive distribution agreement with specialist IVF supplier INVIDO LAB s.r.o. ("INVIDO") covering the Czech Republic, Slovakia and Kazakhstan.

The agreement adds €416,200 (~A$674,000) in minimum contracted purchases over the initial three-year term, with annual minimums increasing from ~A$139,000 in Year 1 to ~A$310,000 in Year 3 as Felix™ adoption develops.

This growing commitment supports Memphasys' strategy of building an expanding installed base of Felix™ Systems and recurring revenue through the ongoing use of single-use cartridges.

INVIDO has exclusivity across the Czech Republic, Slovakia and Kazakhstan for Felix™ cartridges and consoles, subject to agreed minimum purchase and other commercial performance requirements.

Experienced IVF distribution partner

Headquartered in Brno, Czech Republic, INVIDO LAB is a specialist supplier of IVF and laboratory equipment and consumables. INVIDO is market-ready, with established IVF clinic accounts and relationships, an active fertility-sector presence and local technical support across the contracted territories, enabling Memphasys to commence Felix™ commercialisation immediately and accelerate adoption.

The company supplies and supports laboratory technologies across the Czech Republic, Slovakia, Germany and Kazakhstan, with dedicated IVF expertise and technical service capabilities. Its established fertility-sector presence provides Memphasys with a specialised commercial partner to introduce and support Felix™ across the Czech Republic, Slovakia and Kazakhstan.

Under the agreement, INVIDO will lead the commercial development of Felix™ across the contracted territories, supported by Memphasys' newly established European commercial team. INVIDO will leverage its existing relationships with IVF clinics, fertility centres, embryologists and fertility specialists to drive adoption, while providing first-line customer and technical support. Memphasys' European team will work alongside INVIDO to support market development, product training and ongoing commercial and technical activities.

European commercial capability strengthened

Memphasys has strengthened its European commercial capability with the appointment of Arne Schierau as Director, Commercial Operations Europe. Arne brings extensive reproductive health and life sciences experience, including senior roles with Nexpring Health, Fujifilm Biocare Europe and Affymetrix.

Based in Europe, Arne will lead the Company's commercial activities across the region, working directly with commercial partners, clinics and industry stakeholders to accelerate market development, Felix™ adoption and sales. His appointment provides Memphasys with dedicated on-the-ground commercial capability to support its expanding European distribution network, including the newly appointed INVIDO territories, and will form the cornerstone of the Company's planned expansion of its European commercial team as this strategically important market continues to grow.

Marjan Mikel, Chair of the Memphasys Commercialisation Committee, commented:

"Our European expansion momentum continues. This agreement adds three markets and about A$674,000 in minimum contracted purchases, supported by our newly employed European commercial leader.

.

"We are doing exactly what we set out to do, expanding our footprint, getting Felix™ into more IVF clinics and building a growing base of recurring cartridge revenue."

Established and growing IVF markets

The agreement provides Memphasys with exposure to established assisted reproduction markets across the Czech Republic, Slovakia and Kazakhstan.

The Czech Republic has a well-established assisted reproduction sector and is also a destination for patients travelling internationally for fertility treatment. The market comprises 48 ART centres, which performed approximately 54,300 ART cycles in 2023.[1]

Slovakia is also demonstrating growing utilisation of assisted reproduction, with 8,288 ART cycles reported in 2024, an increase of 25% compared with 2022.[2]

---

[1] Czech National Health Information Portal (NZIP), National Register of Reproductive Health – Assisted Reproduction Module, *Cycles of Assisted Reproduction and Their Success in the Czech Republic*, data to 31 December 2023.

[2] National Health Information Centre of the Slovak Republic (NCZI), Assisted Reproduction in the Slovak Republic 2024, published 10 December 2025.

Kazakhstan represents another substantial fertility market within INVIDO's commercial footprint. 31 ART clinics currently operate nationally, with the latest published national registry reporting 27,012 ART cycles in 2021.[3]

Government support is also helping underpin access to fertility treatment in Kazakhstan, with 7,000 publicly funded IVF/ICSI treatment quotas available annually and 19 ART clinics participating in the government-funded program.[4]

Together, these markets provide a sizeable potential opportunity for Felix™ as Memphasys and INVIDO work to establish adoption among IVF clinics, embryologists and fertility specialists.

INVIDO LAB Managing Director Luděk Homola said:

"We are pleased to partner with Memphasys to bring Felix™ to IVF clinics across the Czech Republic, Slovakia and Kazakhstan.

"Felix™ combines strong clinical outcomes with speed, ease of use and standardisation to help our IVF clients help families achieve their dream of having a baby; a goal that sits at the heart of INVIDO's values and everything we do in IVF."

Commercial terms

The distribution agreement has an initial term of three years and provides INVIDO with exclusivity for the Czech Republic, Slovakia and Kazakhstan, subject to achievement of agreed minimum purchase quantities and other performance requirements.

Period	**Minimum purchase commitment[5]**
Year 1	€86,000 (~A$139,000)
Year 2	€138,600 (~A$225,000)
Year 3	€191,600 (~A$310,000)
Total three-year minimum	**€416,200 (~A$674,000)**

The minimum purchase commitments increase progressively over the three-year term. Felix™ cartridges are single-use products, providing the potential for recurring consumables revenue as utilisation increases across participating IVF clinics.

The agreement includes quarterly ordering requirements and is subject to standard commercial terms relating to regulatory compliance, training, customer support, reporting, product supply and termination.

Memphasys is also in advanced discussions with a number of potential commercial partners across priority international markets. As previously advised, the Company remains confident of securing further important commercial relationships in the near term as it continues to

[3] Kazakhstan National Registry of Assisted Reproductive Technologies, Assisted Reproductive Technologies in Kazakhstan (National Registry Data, 2021); Government of the Republic of Kazakhstan, current ART clinic information.
[4] Government of the Republic of Kazakhstan / Ministry of Health, Añsagan Säbi IVF program and government-funded IVF clinic information.
[5] Australian dollar amounts are approximate and have been converted at an exchange rate of €1.00 = A$1.62 as at 16 September 2026. Actual Australian dollar amounts may vary depending on exchange rates at the time of payment.

expand the global commercial footprint of Felix™. The Company looks forward to updating shareholders as these discussions progress.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby
Chapter One Advisors
Tel: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys's current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties and are not guarantees of future performance. Memphasys cautions shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.